Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)

NCT00050336 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

702

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-small-cell Lung
Metastases, Neoplasm

Interventions

DRUG: Lonafarnib (SARASAR)

Sponsor

Merck Sharp & Dohme LLC